Second-line Cabozantinib and Atezolizumab in Patients With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma

Sponsor
National Taiwan University Hospital
Study ID
NCT05007613
Phase
PHASE2
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
20 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

To demonstrate that combination of cabozantinib and atezolizumab is safe and efficacious in patients with recurrent/metastatic esophageal squamous cell carcinoma.

Key Dates

Start date
Jun 23, 2021
Status verified
Dec 2024
Primary completion
Jul 17, 2024
Completion
Dec 1, 2024

Study Design

Enrollment
24 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: cabozantinib plus atezolizumab
    cabozantinib 40mg PO QD atezolizumab 1200mg IVD 30-60mins Q3W

Primary Outcome Measure

Overall response rate (ORR) [ Time Frame: at least 3 weeks after the first treatment ]

Related Studies